Future Security for Iraq

Streaming audio requires RealPlayer.The University Archives has determined that this item is of continuing value to OSU's history.Walter B. Slocombe was, from May to November 2003, Senior Advisor and Director for Security Affairs (National Security and Defense) in the Coalition Provisional Authority for Iraq. Following his return from Iraq, he returned to his position as a partner at the Washington, DC, law firm of Caplin & Drysdale, Chartered, from which he was on leave during his service. At CPA, he supervised the program for creating a new Iraqi Army and for planning the new armed forces of the country, assisted in the coordination of other programs to establish new or reformed security services for Iraq, oversaw the program for paying interim stipends to former Iraqi military personnel, and advised the Iraqi interim authorities on setting up national security institutions and procedures suitable for the new Iraq.Ohio State University. Mershon Center for International Security Studiesweb page announcement, streaming audio, photo

36-month clinical outcomes of patients with venous thromboembolism:GARFIELD-VTE

Background: Venous thromboembolism (VTE), encompassing both deep vein thrombosis (DVT) and pulmonary embolism (PE), is a leading cause of morbidity and mortality worldwide. Methods: GARFIELD-VTE is a prospective, non-interventional observational study of real-world treatment practices. We aimed to capture the 36-month clinical outcomes of 10,679 patients with objectively confirmed VTE enrolled between May 2014 and January 2017 from 415 sites in 28 countries. Findings: A total of 6582 (61.6 %) patients had DVT alone, 4097 (38.4 %) had PE ± DVT. At baseline, 98.1 % of patients received anticoagulation (AC) with or without other modalities of therapy. The proportion of patients on AC therapy decreased over time: 87.6 % at 3 months, 73.0 % at 6 months, 54.2 % at 12 months and 42.0 % at 36 months. At 12-months follow-up, the incidences (95 % confidence interval [CI]) of all-cause mortality, recurrent VTE and major bleeding were 6.5 (7.0–8.1), 5.4 (4.9–5.9) and 2.7 (2.4–3.0) per 100 person-years, respectively. At 36-months, these decreased to 4.4 (4.2–4.7), 3.5 (3.2–2.7) and 1.4 (1.3–1.6) per 100 person-years, respectively. Over 36-months, the rate of all-cause mortality and major bleeds were highest in patients treated with parenteral therapy (PAR) versus oral anti-coagulants (OAC) and no OAC, and the rate of recurrent VTE was highest in patients on no OAC versus those on PAR and OAC. The most frequent cause of death after 36-month follow-up was cancer (n = 565, 48.6 %), followed by cardiac (n = 94, 8.1 %), and VTE (n = 38, 3.2 %). Most recurrent VTE events were DVT alone (n = 564, 63.3 %), with the remainder PE, (n = 236, 27.3 %), or PE in combination with DVT (n = 63, 7.3 %). Interpretation: GARFIELD-VTE provides a global perspective of anticoagulation patterns and highlights the accumulation of events within the first 12 months after diagnosis. These findings may help identify treatment gaps for subsequent interventions to improve patient outcomes in this patient population.</p

Does Europe Need a New Missile Defence System? ESF Working Papers No. 27, November 2007

US plans for a ballistic missile defence system in Europe have given rise to opposition in Russia and tensions in Europe. While some argue that the defence shield is needed to protect Europe against new threats from the proliferation of long-range missiles and nuclear weapons (chiefly from Iran and North Korea), critics hold that the project may pose a threat to Russia’s security and provoke yet another arms race. In this ESF Working Paper, Russian, European and American experts give their perspectives on the controversial US defence initiative, each analysing the strategic rationale for the system and the impact on international relations

Pre-emptive Military Action and the Legitimate Use of Force. ESF Working Paper No. 11, 1 February 2003

No abstract